Xu Chong, Li Moran, Meng Weilun, Han Jun, Zhao Song, Tang Jiamin, Yang Haotian, Maimaitiaili Rusitanmujiang, Teliewubai Jiadela, Yu Shikai, Chi Chen, Fan Ximin, Xiong Jing, Zhao Yifan, Xu Yawei, Zhang Yi
Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
J Pers Med. 2023 Jan 30;13(2):261. doi: 10.3390/jpm13020261.
With the epidemic of risk factors such as unhealthy lifestyle, obesity and mental stress, the prevalence of hypertension continues to rise across the world. Although standardized treatment protocols simplify the selection of antihypertensive drugs and ensure therapeutic efficacy, the pathophysiological state of some patients remains, which may also lead to the development of other cardiovascular diseases. Thus, there is an urgent need to consider the pathogenesis and selection of antihypertensive drug for different type of hypertensive patients in the era of precision medicine. We proposed the REASOH classification, based on the etiology of hypertension, including renin-dependent hypertension, elderly-arteriosclerosis-based hypertension, sympathetic-active hypertension, secondary hypertension, salt-sensitive hypertension and hyperhomocysteinemia hypertension. The aim of this paper is to propose a hypothesis and provide a brief reference for the personalized treatment of hypertensive patients.
随着不健康生活方式、肥胖和精神压力等危险因素的流行，高血压在全球的患病率持续上升。尽管标准化治疗方案简化了抗高血压药物的选择并确保了治疗效果，但一些患者的病理生理状态仍然存在，这也可能导致其他心血管疾病的发生。因此，在精准医学时代，迫切需要考虑不同类型高血压患者的发病机制和抗高血压药物的选择。我们基于高血压的病因提出了REASOH分类，包括肾素依赖性高血压、老年动脉硬化性高血压、交感神经活性增高型高血压、继发性高血压、盐敏感性高血压和高同型半胱氨酸血症性高血压。本文的目的是提出一个假设，并为高血压患者的个体化治疗提供简要参考。
